Johnson & Johnson (JNJ) Stock Price & AI Analysis

$149.61
$3.25
(2.22%)
Pharmaceuticals

NYSE USA

May 16, 5:45 PM EDT
  • Market Cap.
    360.54B
  • Volume
    7.89M
  • Avg. Volume
    9.75M
  • Target Price
    $170.84
  • 52W Range
    140.68 - 169.99
  • RSI (14)
    40.48
  • Beta
    0.39
  • PEG Ratio
    2.82
  • SMA 20
    -3.18%
  • SMA 50
    -5.02%
  • SMA 200
    -4.69%
  • Insider Owner
    0.14%
  • Insider Trans
    -0.57%
  • Institution Owner
    73.29%
  • Institution Trans
    0.57%
  • Short Interest
    19.68%
  • EPS next Y
    4.61

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Johnson & Johnson | Latest news

Jim Cramer Notes That “People Are Staying Away From” Johnson & Johnson

Cramer noted that investors are skirting Johnson & Johnson (NYSE:JNJ) because of worries regarding...

Insider Monkey - 3 hours ago

Is Johnson & Johnson’s -0.20% Fall This Year Is A Better Investing Opportunity?...

In recent trading session, Johnson & Johnson (NYSE:JNJ) saw 1.68 million shares changing hands at last check today with its beta currently measuring 0.39. Company’s recent per share price level ...

Marketing Sentinel - 3 hours ago

Here's Why Johnson & Johnson (JNJ) is a Strong Value Stock

Johnson & Johnson (JNJ) Johnson & Johnson’s biggest strength is its diversified business model. It...

Zacks - 8 hours ago

Why Is Johnson & Johnson (JNJ) Down 4.9% Since Last Earnings Report?

A month has gone by since the last earnings report for Johnson & Johnson (JNJ). Shares have lost...

Zacks - 1 day ago

If You Invested $25,000 In Johnson & Johnson (JNJ) 20 Years Ago, This Is How...

Companies with strong products, good management, solid earnings and growth trends, and a history of...

247wallstcom - 1 day ago

Johnson & Johnson (JNJ) Stock Price and Analyst Predictions – News Heater

Johnson & Johnson (NYSE: JNJ) has a price-to-earnings ratio that is above its average at 17.25x. The stock price of Johnson & Johnson (NYSE: JNJ) has surged by 0.61 when compared to previous ...

NewsHeater - 5 days ago

Is Johnson & Johnson (JNJ) the Best Pharma Stock to Invest in Amid the Domestic...

We recently published a list of Domestic Manufacturing Boom: 12 Best Pharma Stocks to Invest in Now....

Insider Monkey - 3 days ago

Is Johnson & Johnson (JNJ) the Best Income Stock to Invest in Now?

We recently published a list of the Best Income Stocks to Invest in Now. In this article, we are...

Insider Monkey - 7 days ago

Nachawati Law Group Files New Ovarian Cancer Lawsuits Against Johnson & Johnson...

Following a third failed bankruptcy maneuver by Johnson & Johnson (NYSE: JNJ), trial lawyers with Dallas-based Nachawati Law Group have filed three new lawsuits on behalf of women who developed ...

Morningstar - 24 hours ago

J&J Oral Psoriasis Drug Meets Primary Goal in Late-Stage Study

Data from a late-stage study shows that treatment with JNJ's icotrokinra helps achieve significant...

Zacks - 4 days ago